Kabra Drugs Ltd
Kabra Drugs Ltd (KABRADG) last reported results for the quarter ended Jun 2026, with sales of ₹46.22 crore and net profit of ₹2.12 crore. The stock last traded at ₹17.9, a market capitalisation of ₹42.4 crore, on a P/E of 5.58. Over the past 52 weeks the stock has ranged between ₹15.5 and ₹35.5. Figures are as of 6 Oct 2026 and are not real time.
Kabra Drugs Ltd share price and key metrics
- Current price
- ₹17.9
- Market cap
- ₹42.4 cr
- Stock P/E
- 5.58
- Book value
- ₹12.5
- ROE
- 18.3%
- ROCE
- 20.8%
- Dividend yield
- 0.00%
- 52w high / low
- 35.5/15.5
Metrics as of 6 Oct 2026. Not real time.
Track Kabra Drugs Ltd
Cruxal reads every Kabra Drugs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Kabra Drugs Ltd growth and returns
- 10 Years
- 25%
- 5 Years
- %
- 3 Years
- %
- TTM
- 1744%
- 10 Years
- 67%
- 5 Years
- 97%
- 3 Years
- 155%
- TTM
- 823%
- 10 Years
- 11%
- 5 Years
- 28%
- 3 Years
- 52%
- 1 Year
- 12%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 8%
- Last Year
- 18%
Kabra Drugs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹46.22 cr, up 546.4% from ₹7.15 cr a year earlier. Net profit turned positive at ₹2.12 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 7.15 | 19.76 | 30.42 | 35.41 | 46.22 |
| Expenses | 0.4 | 0.53 | 0.24 | 7.67 | 17.72 | 27.99 | 34.07 | 43.43 |
| Operating profit | -0.4 | -0.53 | -0.24 | -0.52 | 2.04 | 2.43 | 1.34 | 2.79 |
| OPM % | — | — | — | -7.27% | 10.32% | 7.99% | 3.78% | 6.04% |
| Other income | 0 | 0 | 0.64 | 0.02 | 0.18 | 0.18 | 0.11 | 0.08 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 |
| Depreciation | 0 | 0 | 0.01 | 0 | 0.01 | 0.01 | 0.02 | 0.02 |
| Profit before tax | -0.4 | -0.53 | 0.39 | -0.5 | 2.21 | 2.6 | 1.42 | 2.84 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 16.74% | 1.54% | 25.35% | 25.35% |
| Net profit | -0.4 | -0.54 | 0.39 | -0.5 | 1.84 | 2.57 | 1.06 | 2.12 |
| EPS (₹) | -0.40 | -0.54 | 0.16 | -0.21 | 0.78 | 1.08 | 0.45 | 0.89 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Kabra Drugs Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8 | 2 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 93 | 132 |
| Operating profit | 0 | -1 | -0 | -0 | -0 | -0 | -0 | -1 | -2 | 5 | 9 |
| OPM % | 6% | -57% | — | -150% | — | — | -3,400% | — | — | 6% | 7% |
| Net profit | 0 | -2 | -0 | -0 | -0 | -0 | -0 | -1 | -1 | 5 | 8 |
| EPS (₹) | 0.30 | -5.38 | -0.36 | -0.14 | -0.41 | -0.43 | -0.77 | -1.69 | -0.46 | 2.09 | 3.20 |
TTM is the trailing twelve months to the most recent quarter.
Kabra Drugs Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 24 | 24 |
| Reserves | -2 | -4 | -4 | -4 | -5 | -5 | -5 | -3 | 1 | 6 |
| Borrowings | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 1 |
| Other liabilities | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 2 | 0 | 56 |
| Total liabilities | 6 | 2 | 1 | 1 | 1 | 1 | 1 | 5 | 25 | 86 |
| Fixed assets | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 5 | 25 | 85 |
| Total assets | 6 | 2 | 1 | 1 | 1 | 1 | 1 | 5 | 25 | 86 |
As reported by the company. Total assets equal total liabilities by construction.
Kabra Drugs Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -5 | -9 |
| Cash from investing | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -1 |
| Cash from financing | -0 | -1 | 0 | -0 | 0 | 0 | 0 | 3 | 23 | 0 |
| Net cash flow | 0 | 0 | -0 | 0 | 0 | -0 | 0 | 3 | 19 | -11 |
| Free cash flow | 0 | 1 | -0 | -0 | -0 | -0 | -0 | -0 | -5 | -10 |
| CFO / operating profit | 73% | 10% | 138% | 100% | 167% | 72% | 100% | 28% | 274% | -173% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Kabra Drugs Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 7% | -44% | -19% | -9% | -27% | -29% | -53% | -43% | -8% | 21% |
| Debtor days | 141 | 254 | -11,406 | — | — | — | — | — | — | 279 |
| Inventory days | 17 | 0 | 0 | — | — | — | — | — | — | 0 |
| Days payable | 97 | — | — | — | — | — | — | — | — | — |
| Cash conversion cycle | 61 | 254 | -11,406 | — | — | — | — | — | — | 279 |
| Working capital days | 34 | -28 | -912 | — | — | — | — | — | — | 66 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Kabra Drugs Ltd shareholding pattern
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Public | 100.01% | 100.00% | 100.00% | 100.01% | 100.00% | 100.00% | 100.00% | 100.00% |
| No. of shareholders | 7,367 | 7,343 | 7,435 | 7,449 | 8,098 | 8,862 | 9,185 | 9,680 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Kabra Drugs Ltd corporate filings
- Aanjaay Industries Limited conducts successful remote e-voting at AGM with 99.87% approval for financial resolutionsAGM/EGMlow impact
Cruxal's analysis: Aanjaay Industries Limited, formerly Kabra Drugs Limited, held its 37th AGM on 30th…
Read the full analysis - Aanjaay Industries Limited holds AGM with no immediate financial disclosures; upcoming resolutions on director appointments and compliance highlightedAGM/EGMlow impact
Cruxal's analysis: Aanjaay Industries Limited conducted its 37th Annual General Meeting on 30th September…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Aanjaay Industries Limited Announces 37th Annual General Meeting (AGM) for September 30, 2026Company Updatelow impact
Cruxal's analysis: Aanjaay Industries Limited has issued a formal notice for its 37th Annual General Meeting…
Read the full analysis - Kabra Drugs Ltd files Annual Report for FY 2025-2026Otherslow impact
Cruxal's analysis: Kabra Drugs Ltd has submitted its Annual Report for the financial year 2025-2026 in…
Read the full analysis - Aanjaay Industries Limited announces 37th Annual General Meeting for September 30, 2026AGM/EGMlow impact
Cruxal's analysis: Aanjaay Industries Limited has issued a formal notice for its 37th Annual General Meeting…
Read the full analysis - Kabra Drugs Ltd announces book closure and e-voting schedule for upcoming corporate meetingCorp. Actionlow impact
Cruxal's analysis: Kabra Drugs Ltd has issued a routine notification regarding the book closure period and…
Read the full analysis - Aanjaay Industries Limited Appoints M/s Karthik L & Associates as Internal Auditor for FY 2026-2027Company Updatelow impact
Cruxal's analysis: Aanjaay Industries Limited has formally appointed M/s Karthik L & Associates as the…
Read the full analysis - Aanjaay Industries Limited Appoints Secretarial Auditor for FY 2026-2027 to 2030-2031Company Updatelow impact
Cruxal's analysis: Aanjaay Industries Limited has announced the appointment of Mrs. Twinkle Agarwal, a…
Read the full analysis - Aanjaay Industries Limited Announces 37th AGM Details, Board Appointments, and Auditor Re-appointmentsBoard Meetinglow impact
Cruxal's analysis: Aanjaay Industries Limited has announced the scheduling of its 37th Annual General…
Read the full analysis - Kabra Drugs Ltd announces change in registered office addressCompany Updatelow impact
Cruxal's analysis: Kabra Drugs Ltd has filed an intimation regarding the change of its registered office…
Read the full analysis - Aanjaay Industries Limited schedules Board Meeting for 02nd September 2026 to approve Annual General Meeting agenda and director appointmentsBoard Meetinglow impact
Cruxal's analysis: Aanjaay Industries Limited has announced a board meeting scheduled for 02nd September…
Read the full analysis - Kabra Drugs Ltd announces reconstitution of Board and Committees under SEBI LODR regulationsCompany Updatelow impact
Cruxal's analysis: Kabra Drugs Ltd has filed a disclosure regarding the reconstitution of its Board of…
Read the full analysis - Kabra Drugs Ltd publishes newspaper advertisement for June 2026 quarter resultsCompany Updatelow impact
Cruxal's analysis: Kabra Drugs Ltd has fulfilled its regulatory obligation under Regulation 30 of the SEBI…
Read the full analysis - Aanjaay Industries Limited (formerly Kabra Drugs Limited) announces resignation of Director Ms. Anand AnithaCompany Updatelow impact
Cruxal's analysis: Aanjaay Industries Limited has formally notified the exchange regarding the resignation…
Read the full analysis - Kabra Drugs Ltd confirms non-applicability of SEBI Regulation 32Company Updatelow impact
Cruxal's analysis: Kabra Drugs Ltd has submitted an undertaking confirming that Regulation 32 of the SEBI…
Read the full analysis - Aanjaay Industries reports strong Q1 FY27 performance with revenue of 46.22 crore and net profit of 2.12 croreResulthigh impact
Cruxal's analysis: Aanjaay Industries Limited reported a significant turnaround for the quarter ended 30th…
Read the full analysis - Aanjaay Industries Limited reports strong Q1 FY2027 performance with net profit of 2.12 croreBoard Meetinghigh impact
Cruxal's analysis: Aanjaay Industries Limited reported a significant improvement in financial performance…
Read the full analysis - Aanjaay Industries Limited schedules Board Meeting for August 12, 2026, to approve Q1 FY27 financial results and note director resignationBoard Meetinglow impact
Cruxal's analysis: Aanjaay Industries Limited has formally intimated the BSE regarding a Board Meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.